《异动股》国泰/国航/南航探顶 米兰站飙四成
虽然本港新冠肺炎疫情严峻,但英国将於下周率先为当地高危人群接种辉瑞与德国药厂BioNTech研发的新冠肺炎疫苗,市场憧憬疫苗短期内於全球面世。本港航空股造好,尤其是国泰航空(00293.HK)三连涨,最高见7.74元,创近半年高,现造7.72元,续升3.6%,成交增至952万股。国泰持股逾18%的国航(00753.HK)也三连涨兼屡探顶,最高见6.8元,创近九个月高,现造6.67元,续升1.7%。东航(00670.HK)及南航(01055.HK)高见3.68元及5.13元,现造3.66元及5.12元,回升3.1%及4.3%,後者创逾十个月高,成交分别增至2,010万股及2,757万股。
此外,米兰站(01150.HK)三连涨,今天股价更发力突破牛熊线(0.176元),最高见0.23元,现造0.191元,急升40%,成交激增至6,176万股,为逾三年罕见。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.